Skip to content
DataLookout
Menu

NCT07486102

A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 21 words Show 5 more changesShow less
    • Trial completed
    • Final enrollment: 34 participants (planned 44)
    • Primary completion date changed from estimate of Feb 26, 2027 to Oct 30, 2026
    • Study completion date changed from estimate of Feb 27, 2027 to Oct 31, 2026
    • Site details revised
  2. Notable Recruitment opened
    • Start date changed from estimate of May 4, 2026 to May 1, 2026
    • Site details revised
    v5
  3. Minor Start date: Apr 15, 2026 to May 4, 2026v4
  4. Notable Eligibility criteria expanded, about 65 wordsv3
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Timeframe: Up to 8 days
Maximum measured concentration of the analyte in plasma (Cmax)
Timeframe: Up to 8 days

Secondary (1)

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)

Arms and interventions

Participants with mild hepatic impairment (Child-Pugh A)Experimental
Participants with moderate hepatic impairment (Child-Pugh B)Experimental
Participants with severe hepatic impairment (Child-Pugh C)Experimental
Participants with normal hepatic functionExperimental

Drugs: BI 3000202

Sites

1 site in 1 country

  • American Research Corporation at the Texas Liver InstituteSan Antonio, Texas, United States